Korea United Pharm유나이티드제약
033270 · KOSPI · ₩033270 · 유나이티드제약
₩16,850▲ ₩90 (0.54%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩289B | ₩289B | ₩279B | ₩263B | ₩221B |
| Cost of sales | ₩128B | ₩125B | ₩120B | ₩117B | ₩98B |
| Gross profit | ₩161B | ₩164B | ₩159B | ₩145B | ₩123B |
| Operating income | ₩50B | ₩56B | ₩55B | ₩48B | ₩33B |
| Net income | ₩38B | ₩32B | ₩48B | ₩45B | ₩29B |
| Net income to shareholders | ₩38B | ₩32B | ₩48B | ₩45B | ₩29B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩519B | ₩474B | ₩469B | ₩418B | ₩380B |
| Current assets | ₩269B | ₩245B | ₩245B | ₩224B | ₩204B |
| Cash and equivalents | ₩40B | ₩34B | ₩24B | ₩27B | ₩61B |
| Total liabilities | ₩65B | ₩68B | ₩90B | ₩80B | ₩79B |
| Current liabilities | ₩48B | ₩48B | ₩73B | ₩66B | ₩61B |
| Borrowings | ₩13B | ₩15B | ₩39B | ₩29B | ₩32B |
| Total equity | ₩455B | ₩406B | ₩379B | ₩338B | ₩301B |
| Shareholders' equity | ₩455B | ₩406B | ₩379B | ₩338B | ₩301B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩51B | ₩27B | ₩50B | ₩64B | ₩44B |
| Capital spending | ₩23B | ₩21B | ₩31B | ₩22B | ₩11B |
| Free cash flow | ₩28B | ₩5.8B | ₩19B | ₩41B | ₩33B |
| Dividends paid | ₩6.6B | ₩6.1B | ₩5.9B | ₩5.5B | ₩5.2B |
Consolidated where available. Amounts in won.
Also known as: Korea United Pharm / 유나이티드제약 / 033270 / KRX:033270
Source: KRX statistical information